Cancer Researchers Identify Key Metabolic Pathway in Cell Nucleus

A research team at Roswell Park Comprehensive Cancer Center has uncovered a previously unknown metabolic pathway critical to cancer progression, offering potential new avenues for targeted therapies. Published in *Nature Communications*, the study reveals how this pathway drives tumor growth by activating specific genes, and demonstrates that inhibiting it significantly hinders cancer cells’ ability to proliferate and metastasize. The findings could inform the development of interventions aimed at disrupting this mechanism to slow or halt malignancies.

The researchers employed advanced genomic and metabolic profiling techniques to identify the pathway, which operates through a cascade of enzymatic reactions that fuel gene expression linked to cancer aggressiveness. Experiments using CRISPR gene-editing and metabolomic analysis across multiple cancer models showed that blocking key components of the pathway reduced tumor cell viability and migration. Notably, the pathway’s activity was observed in diverse cancer types, suggesting its broad relevance. The study also highlights potential biomarkers for patient stratification, as variations in pathway activity may predict treatment responsiveness.

This discovery underscores the complex interplay between metabolism and cancer biology, providing a foundation for therapies targeting metabolic vulnerabilities. While further research is needed to translate these findings into clinical applications, the work represents a significant step toward understanding how metabolic reprogramming sustains tumor progression. The team is now exploring drug candidates that selectively interfere with the pathway, with the goal of advancing preclinical trials.